Hsing Pang Hsieh

HP Hsieh 2Hsing-Pang Hsieh, Ph.D.
Distinguished Investigator
Director
Institute of Biotechnology and Pharmaceutical Research
Email: hphsieh@nhri.edu.tw
website:https://www.hphsiehlab.com/

 

EDUCATION

  • Ph.D., Organic Chemistry, State University of New York (1993)
  • M.S., Organic Chemistry, National Tsing Hua University (1987)
  • B.S., Chemistry, National Tsing Hua University (1985)

PROFESSIONAL EXPERIENCES

  • Distinguished Investigator & Director, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes. (2023/1-present)
  • Jointly Appointed Investigator,Biomedical Translation Research Center (BioTReC), National Biotechnology Research Park (NBRP), Academia Sinica. (2023/1-present)
  • Jointly Appointed Professor, Department of Chemistry, National Tsing Hua University. (2014/8 – present)
  • Jointly Appointed Professor, Department of Biological Science & Technology, National Chiao Tung University. (2017/8 – present)
  • Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes. (2007/9 – 2022/12)
  • Group Leader, Division of Research & Development, Central Epidemic Command Center. (2020/7-present)
  • Research Fellow/Deputy Director, Biomedical Translation Research Center (BioTReC), National Biotechnology Research Park (NBRP), Academia Sinica. (2020/1-2022/12)
  • Promoter, Value-Added MedChem Innovation Center, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes. (2018 – 2019)
  • Executive Council Member, Chemical Society Located in Taipei. (2017-2020)
  • Associate Director, Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes. (2015/4-2019/12)
  • Acting Director, Technology Transfer and Incubation Center, National Health Research Institutes. (2018/9-2019/3)
  • Director, Department of Research Planning and Development, National Health Research Institutes. (2012/2-2014/10)
  • Director, Technology Transfer and Incubation Center, National Health Research Institutes. (2009/3-2012/2)
  • Chief, Library, National Health Research Institutes. (2007/11-2009/3)
  • Associate Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes. (2003/2 – 2007/9)
  • Adjunct Professor, Department of Chemistry, National Tsing Hua University. (2008-2014)
  • Assistant Investigator, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes. (1998/5-2003/2)
  • Post-Doctoral Fellow, Institute of Biological Chemistry, Academia Sinica. (1996-1997)
  • Research Associate, Department of Chemistry, Boston College, USA. (1994-1995)

RESEARCH INTERESTS

Dr. Hsieh’s research interests are deeply involved in three different areas, namely cancer, infectious diseases, and diabetes. In particular, tubulin and kinase are mainly two drug targets for cancer research. Five antiviral projects, including anti-hepatitis B virus (HBV), anti-human cytomegalovirus (HCMV), anti-hepatitis C virus (HCV), anti-SARS, and anti-flu projects and two antidiabetes projects including Peroxisome Proliferator- Activated Receptors (PPARs) agonists and dipeptidylpeptidase 4 (DPP4) inhibitors were also involved in.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Hsing-Pang Hsieh’s lab specializes in drug discovery and developing on novel anticancer drugs “From Bench to Bedside”. I have published 125 scientific journals including 29 papers published in J. Med. Chem., top-one in the field of medicinal chemistry, and obtained 62 composition patents granted worldwide. More importantly, I invented three clinical candidates (A) DBPR112, which was licensed to AnBogen Therapeutics, was approved for IND by US FDA and TFDA on April 8 and August 23, 2016 and is undergoing Phase I clinical trial in Taiwan since July 2017; (B) DBPR114 was approved for IND by US FDA on July 20, 2017; (C) DBPR104, which was licensed to SynCore Bio, was completed Phase II clinical trial in Taiwan.

HONORS & AWARDS

  • 2023 National Academy of Inventors (NAI) fellow
  • 2022 Chemical Society Located in Taipei Award
  • 2019 NBRP BioMed Start-up Challenge Pitch (2nd Award)
  • 2018 MOST Future Tech Award
  • 2018 Asian CORE Program (ACP) Lectureship Award
  • 2017 MOST Outstanding Research Award
  • 2016 Wang Ming-Ning Award
  • 2015 NHRI Outstanding Research Achievement Award
  • 2014 Lifetime Achievement of International Outstanding Invention Award
  • 2013 TECO Award
  • 2013 National Innovation Award
  • 2011 Dr. T. C. Tung Cancer Basic Research Outstanding Award
  • 2010 NSC Outstanding Awards
  • 2010 National Invention and Creation Award
  • 2008 TienTe Lee Outstanding Awards
  • 2006 NHRI Young Scientist Award

PUBLICATIONS(from 2012)

2023

  1. Li, M. C.; Coumar, M. ; Lin, . Y.; Lin, Y. S.; Huang, G. L.; Chen, C. H.; Lien, T. W.; Wu, Y. W.; Chen, Y. T.; Chen, C. P.; Huang, Y. C.; Yeh, K. C.; Yang, C. M.; Kalita, B.; Pan, S. L.; Hsu, T. A.; Yeh, T. K.; Chen, C. T.; Hsieh, H. P.* “Development of Furanopyrimidine-Based Orally Active Third-Generation EGFR Inhibitors for the Treatment of Non-Small Cell Lung Cancer” Med. Chem. 2023, accepted (corresponding author) (SCI: 8.039)(3/63, CHEMISTRY, MEDICINAL)

2022

  1. Kumari, M.; Lu, R. M.; Li, M. C.; Huang, J. L.; Hsu, F. F.; Ko, S. H.; Ke, F. Y.; Su, S. C.; Liang, K. H.; Yuan, J. P. Y.; Chiang, H. L.; Sun, C. P.; Lee, I. J.; Li, W. S.; Hsieh, H. P.; Tao, M. H.; Wu, H. C.* “A Critical Overview of Current Progress for COVID‑19: Development of Vaccines, Antiviral Drugs, and Therapeutic Antibodies” Biomed. Sci. 2022, 29, Article number 68. (SCI: 12.771) (24/195, CELL BIOLOGY) Times Cited: 6
  2. Chen, C. M.*; Hsieh, H. P.* “Recent Advances in Total Synthesis of Natural Products by Masked Ortho-benzoquinones” Chin. Chem. Soc. 2022, 69, 1210-1222. (corresponding author) (SCI:1.753) (135/179, CHEMISTRY, MULTIDISCIPLINARY)
  3. Liu, J. S.; Fang, W. K.; Yang, S. M.; Wu, M. C.; Chen, T. J.; Chen, C. M.; Lin, T. Y.; Liu, K. L.; Wu, C. M.; Chen, Y. C.; Chuu, C. P.; Wang, L. Y.; Hsieh, H. P.; Kung, H. J.; Wang, W. C.* “Natural Product Myricetin is a Pan-KDM4 Inhibitor which with Poly Lactic-co-glycolic Acid Formulation Effectively Targets Castration-resistant Prostate Cancer” Biomed. Sci. 2022, 29, Article number 29. (SCI: 12.771) (24/195, CELL BIOLOGY) Times Cited: 1
  4. Lee, R. K.; Li, T. N.; Chang, S. Y.; Chao, T. L.; Kuo, C. H.; Pan, M. Y.; Chiou, Y. T.; Liao, K. J.; Yang, Y.; Wu, Y. H.; Huang, C. H.; Juan, H. F.; Hsieh, H. P.; Wang, L. H.* “Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2” J. Mol. Sci. 2022, 23, 4050. (SCI: 6.208) (50/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 7
  5. Lai, Y. L.; Wang, K. H.; Hsieh, H. P.; Yen, W. C.* “Novel FLT3/AURK Multikinase Inhibitor is Efficacious against Sorafenib-refractory and Sorafenib-resistant Hepatocellular Carcinoma” Biomed. Sci. 2022, 29, Article number 5. (SCI: 12.771) (24/195, CELL BIOLOGY)

2021

  1. Lee, K. H.; Yen, W. C.; Lin, W. H.; Wang, P. C.; Lai, Y. L.; Su, Y. C.; Chang, C. Y.; Wu, C. S.; Huang, Y. C.; Yang, C. M.; Chou, L. H.; Yeh, T. K.; Chen, C. T.; Shih, C.; Hsieh, H. P.* “Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model” Med. Chem. 2021, 64, 14477-14497. (corresponding author) (SCI: 8.039)(3/63, CHEMISTRY, MEDICINAL) Times Cited: 9
  2. Huang, C. Y.; Lin, S. Y.; Hsu, T. A.; Hsieh, H. P.*; Huang, M. H.* “Colloidal Assemblies Composed of Polymeric Micellar/Emulsified Systems Integrate Cancer Therapy Combining a Tumor- Associated Antigen Vaccine and Chemotherapeutic Regimens” Nanomaterials, 2021, 11, article 1844. (corresponding author) (SCI: 5.719)(55/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 1
  3. Li, M. C.; Lin, W. H.; Wang, P. C.; Su, Y. C.; Chen, P. Y.; Fan, C. M.; Chen, C. P.; Huang, C. L.; Chiu, C. H.; Chang, L.; Chen, C. T.; Yeh, T. K.; Hsieh, H. P.* “Design and Synthesis of Novel Orally Selective and Type II Pan-TRK Inhibitors to Overcome Mutations by Property-Driven Optimization” J. Med. Chem. 2021, 224, article 113673 (corresponding author) (SCI: 7.088) (5/63, CHEMISTRY, MEDICINAL) Times Cited: 8
  4. Charles, M. R. C.; Li, M. C.; Hsieh, H. P.*; Coumar, M. S.* “Mimicking H3 Substrate Arginine in the Design of G9a Lysine Methyltransferase Inhibitors for Cancer Therapy: A Computational Study for Structure-Based Drug Design” ACS Omega 2021, 6, 6100-6111. (corresponding author) (SCI: 4.132)(73/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 2
  5. Chen, Y. Y.; Zhang, Y. L.; Lee, G. H.; Tsou, L. K.; Zhang, M. M.; Hsieh, H. P.; Chen, J. J.; Ko, C. Y.; Wen, Z. H.; Sung P. J.* “Briarenols W-Z: Chlorine-Containing Polyoxygenated Briaranes from Octocoral Briareum Stechei (Kükenthal, 1908)” Drugs 2021, 19, 77. (SCI: 6.085)(10/63, CHEMISTRY, MEDICINAL) Times Cited: 3
  6. Huynh, T. H.; Lee, G. H.; Tanaka J.; Hsieh, H. P.; Tsou, L. K.; Zhang, M. M.; Kuo, T. J.; Wen, Z. H.; m Lu, C. K.; Sung P. J.* “Chlorinated briarane diterpenoids from octocoral Briareum stechei (Kükenthal, 1908)” Tetrahedron Lett. 2021, 69, 152976. (SCI: 2.032)(36/56, CHEMISTRY, ORGANIC) Times Cited: 1
  7. Taweesak, P.; Thongaram, P.; Kraikruan, P.; Thanetchaiyakup, A.; Chuanopparat, N.; Hsieh, H. P.; Uang, B. J.; Ngernmeesri, P.* “One-Pot Synthesis of Dibenzo[b,f]oxepines and Total Synthesis of Bauhinoxepin C” Org. Chem. 2021, 86, 1955-1963. (SCI: 4.198) (12/56, CHEMISTRY, ORGANIC) Times Cited: 4
  8. Reddy, J. S.; Chen, C. M.; Coumar, M. S.; Sun, H. Y.; Sun, N.; Hsieh, H. P.* “Development of a Robust Scale-up Synthetic Route for BPR1K871: A Clinical Candidate for the Treatment of Acute Myeloid Leukemia and Solid Tumors” Process Res. Dev. 2021, 25, 817-830. (corresponding author) (SCI: 3.858)(27/73, CHEMISTRY, ORGANIC) Times Cited: 2
  9. Syed, S. B.; Lin, S. Y.; Arya, H.; Fu, I. H.; Yeh, T. K.; Charles, M. R. C.; Periyasamy, L.; Hsieh, H. P.*; Coumar, M. S.* “Overcoming Vincristine Resistance in Cancer: Computational Design and Discovery of Piperine Inspired P-glycoprotein Inhibitors” Biol. Drug Des. 2021, 97, 51-66. (corresponding author) (SCI: 2.873)(43/63, CHEMISTRY, MEDICINAL) Times Cited: 3

2020

  1. Li, M. C.; Hsieh, H. P.* “Tumor-agnostic Inhibitors in Oncology: A New Phase for Precision Medicine” Chin. Chem. Soc. 2021, 67, 2216-2224. (corresponding author) (SCI: 1.753) (135/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 1
  2. Arya, H; Yadav, C. S.; Lin, S. Y.; Syed, S. B.; Charles, M. R. C.; Kannadasan, S.; Hsieh, H. P.; Singh, S. S.; Gajurel, P. R.; Coumar, M. S.* “Design of a Potent Anticancer Lead Inspired by Natural Products from Traditional Indian Medicine” Biomol. Struct. Dyn. 2020, 38, 3563-3577. (SCI: 5.235) (100/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 3
  3. Blay, V.*; Li, M. C.; Ho, S. P.; Stoller, M. L.; Hsieh, H. P.; Houston, D. R. “Design of Drug-like Hepsin Inhibitors against Prostate Cancer and Kidney Stones” Pharm. Sin B. 2020, 10, 1309-1320. (SCI: 14.907)(8/279, PHARMACOLOGY & PHARMACY) Times Cited: 4
  4. Lin, S. Y.; Chang, C. F.; Coumar, M. S.; Chen, P. Y.; Kuo, F. M.; Chen, C. H.; Li, M. C.; Lin, W. H.; Kuo, P. C.; Wang, S. Y.; Li, A. S.; Lin, C. Y.; Yang, C. M.; Yeh, T. K.; Song, J. S.; Hsu, J. T. A.; Hsieh, H. P.* “Drug-like Property Optimization: Discovery of Orally Bioavailable Quinazoline-Based Multi-Targeted Kinase Inhibitors” Bioorg Chem. 2020, 98, 103689. (corresponding author) (SCI: 5.307)(8/56, CHEMISTRY, ORGANIC) Times Cited: 6
  5. Lai, C. H.; Chen, R. Y.; Hsieh, H. P.; Tsai, S. J.; Chang, K. C.; Yen, C. J.; Huang, Y. C.; Liu, Y. W.; Lee, J. C.; Lai, Y. C.; Hung, L. Y.*; Lin, B. W.* “A Selective Aurora-A 5′-UTR siRNA Inhibits Tumor Growth and Metastasis” Cancer Lett. 2020, 472, 97-107. (SCI: 9.756)(35/245, ONCOLOGY) Times Cited: 10
  6. Charles, M. R. C.; Mahesh, A.; Lin, S. Y.;Hsieh, H. P.; Dhayalan, A.*; Coumar, M. S.* “Identification of Novel Quinoline Inhibitor for EHMT2/G9a through Virtual Screening” Biochimie. 2020, 168, 220-230. (SCI: 4.372)(140/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 8

2019

  1. Lin, S. Y.; Hsu Yung, C.; Peng, Y. H. ; Ke, Y. Y.; Lin, W. H.; Sun,H. Y.; Kuo, F. M.; Chen, P. Y.; Lien, T. W.; Chen, C. H.; Chu, C. Y.; Wang, S. Y.; Yeh, K. C.; Chen, C. P.; Hsu, J. TA; Wu, S. Y.; Yeh, T. K.; Chen, C. T.; Hsieh, H. P.* “Discovery of Clinical Candidate DBPR112, a Furanopyrimidine-based Epidermal Growth Factor Receptor Inhibitor for the Treatment of Non-Small Cell Lung Cancer” Med. Chem. 2019, 62, 10108-10123. (corresponding author) (SCI: 8.039)(3/63, CHEMISTRY, MEDICINAL) Times Cited: 11
  2. Tseng, P. H.; Sie, Z. L.; Liu, M. C.; Lin, H. S.; Yang, W. Y.; Lin, T. Y.; Hsieh, H. P.; Hung, S. C.; Cheng, C. L.; Wang, H. D.; Chang, H. H.*; Yuh, C. H.* “Identification of Two Novel Small Compounds that Inhibit Liver Cancer Formation in Zebrafish and Analysis of Their Conjugation to Nanodiamonds to Further Reduce Toxicity” Therapeutics 2019, 2, 1900105. (SCI: 5.003)(78/279,PHARMACOLOGY & PHARMACY) Times Cited: 7
  3. Lin, H. H.; Chen, S. J.; Shen, M. R.; Huang, Y. T.; Hsieh, H. P.; Lin, S. Y.; Lin, C. C.; Chang, W. W.; Chang, J. Y.* “Lysosomal Cysteine Protease Cathepsin S is Involved in Cancer Cell Motility by Regulating Store-Operated Ca2+ Entry” Biophys. Acta. Mol. Cell Res. 2019, 1866, 118517. (SCI: 5.011)(110/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 13
  4. Quattrini, L.; Coviello, V.; Sartini, S.; Di Desidero, T.; Orlandi, P.; Ke, Y. Y.; Liu, K. L.; Hsieh, H. P.; Bocci, G.; La Motta, C.* “Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation” Rep. 2019, 9, 9943. (SCI: 4.997)(19/74, MULTIDISCIPLINARY SCIENCES) Times Cited: 3
  5. Ramya, C. C. ; Hsieh, H. P.; Coumar, M. S.* “Delineating the Active Site Architecture of G9a Lysine Methyltransferase through Substrate and Inhibitor Binding Mode Analysis: A Molecular Dynamics Study” J. Biomol. Struct. Dyn. 2019, 37, 2581-2592. (SCI: 5.235) (100/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 9
  6. Charles, M. R. C.; Dhayalan, A.; Hsieh, H. P.; Coumar, M. S.* “Insights for the Design of Protein Lysine Methyltransferase G9a Inhibitors” Future Med. Chem. 2019, 11, 993-1014. (SCI: 4.767) (21/63, CHEMISTRY, MEDICINAL) Times Cited: 17

2018

  1. Chen, C. M.; Shiao, H. Y.; Uang, B. J.; Hsieh, H. P.* “Biomimetic Syntheses of (±)-Isopalhinine A, (±)-Palhinine A, and (±)-Palhinine D” Chem. Int. Ed. Engl. 2018, 57, 15572-15576. (corresponding author) (SCI: 16.823)(15/179, , CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 18 獲得德國蒂姆醫學出版社SYNFACTS主編蘇黎世聯邦理工學院Erick M. Carreira教授選為 “synfact of the month” 作專文介紹 (Synfacts, 2019, 15, 1)。榮獲第十五屆永信李天德醫藥科技獎之「傑出論文獎」。
  2. Ke, Y. Y.; Chang, C. P.; Lin, W. H.; Tsai, C. H.; Chiu, I. C.; Wang, W. P.; Wang, P. C.; Chen, P. Y.; Lin, W. H.; Chang, C. F.; Kuo, P. C.; Song, J. S.; Shih, C.; Hsieh, H. P.*; Chi, Y. H.* “Design and Synthesis of BPR1K653 Derivatives Targeting the Back Pocket of Aurora Kinases for Selective Isoform Inhibition” J. Med. Chem. 2018, 151, 533-545. (corresponding author) (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 8
  3. La Pietra, V.; Sartini, S.; Botta, L.; Antonelli, A.; Ferrari, S. M.; Fallahi, P.; Moriconi, A.; Coviello, V.; Quattrini, L.; Ke, Y. Y.; Hsieh, H. P.; Da Settimo, F.; Novellino, E.; La Motta, C.*; Marinelli, L.* “Challenging Clinically Unresponsive Medullary Thyroid Cancer: Discovery and Pharmacological Activity of Novel RET Inhibitors” J. Med. Chem. 2018, 150, 491-505. (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 10

2017

  1. Syed S. B.; Arya, H.; Fu, I. H.; Yeh, T. K.; Periyasamy, L.;Hsieh, H.P.*; Coumar, M. S.* “Targeting P-glycoprotein: Investigation of Piperine Analogs for Overcoming Drug Resistance in Cancer”. Rep. 2017, 7, 7972. (corresponding author) (SCI:4.997)(19/74, MULTIDISCIPLINARY SCIENCES) Times Cited: 65
  2. Singh, V. K.; Chang, H. H.; Kuo, C. C.; Shiao, H. Y.; Hsieh, H. P.; Coumar, M. S.* “Drug Repurposing for Chronic Myeloid Leukemia: In Silico and In Vitro Investigation of DrugBank Database for Allosteric Bcr-Abl Inhibitors” Biomol. Struct. Dyn. 2017, 35, 1833-1848. (SCI: 5.235) (100/297, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 18

2016

  1. Chang Hsu, Y.; Selvaraj, C. M. ; Wang, W. C.; Shiao, H. Y.; Ke, Y. Y.; Lin, W. H.; Kuo, C. C.; Chang, C. W.; Kuo, F. M.; Chen, P. Y.; Wang, S. Y.; Li, A. S.; Chen, C. H.; Kuo, P. C.; Chen, C. P.; Wu, M. H.; Huang, C. L.; Yen, K. J.; Chang, Y. I.; Hsu, J. T.; Chen, C. T.; Yeh, T. K.; Song, J. S.; Shih, C.; Hsieh, H. P.* “Discovery of BPR1K871, a Quinazoline Based, Multi-kinase Inhibitor for the Treatment of AML and Solid Tumors: Rational Design, Synthesis, In Vitro and In Vivo Evaluation” Oncotarget, 2016, 7, 86239-86256. (corresponding author) Times Cited: 12
  2. C. F.; Lin, W. H.; Ke, Y. Y.; Lin, Y. S.; Wang, W. C.; Chen, C. H.; Kuo, P. C.; Hsu, J. T.; Uang, B. J.*; Hsieh, H. P.* “Discovery of Novel Inhibitors of Aurora Kinases with Indazole Scaffold: In Silico Fragment-based and Knowledge-based Drug Design” Eur. J. Med. Chem. 2016, 124, 186-199. (corresponding author) (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 12
  3. Sarvagalla, S.; Hsieh, H. P.; Coumar, M. S.* “Therapeutic Polymeric Nanoparticles and the Methods of Making and Using thereof: A Patent Evaluation of WO2015036792” Expert Opin. Ther. Pat. 2016, 26, 751-755. (SCI: 6.714)(6/63, CHEMISTRY, MEDICINAL) Times Cited: 2
  4. Sarvagalla, S.; Cheung, C. H. A.; Tsai, J. Y.; Hsieh, H. P.; Coumar, M. S.* “Disruption of Protein-protein Interactions: Hot Spot Detection, Structure-based Virtual Screening and In Vitro Testing for the Anti-cancer Drug Target Survivin. RSC Advances 2016, 6, 31947-31959. (SCI: 4.036)(75/179, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 24

2015

  1. Ke, Y. Y.; Singh, V. K.; Coumar, M. S.; Hsu, Y. C.; Wang, W. C.; Song, J. S.; Chen, C. H.; Lin, W. H.; Wu, S. H.; Hsu, J. T.; Shih, C.; Hsieh H. P.* “Homology Modeling of DFG-in FMS-like Tyrosine Kinase 3 (FLT3) and Structure-based Virtual Screening for Inhibitor Identification” Rep. 2015, 5, 11702. (corresponding author) (SCI:4.997)(19/74, MULTIDISCIPLINARY SCIENCES) Times Cited: 52
  2. Wu, C. H.; Wang, C. J.; Chang, C. P.; Cheng, Y. C.; Song, J. S.; Jan, J. J.; Chou, M. C.; Ke, Y. Y.; Ma, J.; Wong, Y. C.; Hsieh, T. C.; Tien, Y. C.; Gullen, E. A.; Lo, C. F.; Cheng, C.Y.; Liu, Y. W.; Sadani, A. A.;Tsai, C. H.; Hsieh, H. P.; Tsou, L. K.*; Shia, K. S.* “Function-Oriented Development of CXCR4 Antagonists as Selective Human Immunodeficiency Virus (HIV)-1 Entry Inhibitors” Med. Chem. 2015, 58, 1452-1465. (SCI: 8.039)(3/63, CHEMISTRY, MEDICINAL) Times Cited: 23
  3. Sarvagalla, S.; Singh, V. K.; Ke, Y. Y.; Shiao, H. Y.; Lin, W. H.; Hsieh, H. P.; Hsu, J. T.; Coumar, M. S.* “Identification of Ligand Efficient, Fragment-like Hits from an HTS Library: Structure-based Virtual Screening and Docking Investigations of 2H– and 3H-Pyrazolo Tautomers for Aurora Kinase A Selectivity” Comput. Aided Mol. Design 2015, 29, 89-100. (SCI: 4.179)(21/72, BIOPHYSICS) Times Cited: 36

2014

  1. Velu, A. B.; Chen, G. W.; Hsieh, P. T.; Horng, J. T.; Hsu, J. T.; Hsieh, H. P.; Chen, T. C.; Weng, K. F. Shih, S. R.* “BPR-3P0128 Inhibits RNA-dependent RNA Polymerase Elongation and VPg Uridylylation Activities of Enterovirus 71.” Antiviral Res. 2014, 112, 18-25. (SCI: 10.103)(6/37, VIROLOGY) Times Cited: 16
  2. Lee, C. C.; Shiao, H. Y.; Wang, W. C.; Hsieh, H. P.* “Small-molecule EGFR Tyrosine Kinase Inhibitors for the Treatment of Cancer” Opin. Investig. Drugs. 2014, 23, 1333-1348. (corresponding author) (SCI: 6.498)(41/279, PHARMACOLOGY & PHARMACY) Times Cited: 44
  3. Chen, Y. P.; Lin, H. J.; Chen, J. S.; Tsai, M. Y.; Hsieh, H. P.; Chang, J. Y.; Chen, N. F.; Chang, K. C.; Huang, W. T.; Su, W. C.; Yang, S. T.; Chang, W. C.; Hung, L. Y.*; Chen, T. Y.* “CDKN1A-mediated Responsiveness of MLL-AF4-positive Acute Lymphoblastic Leukemia to Aurora Kinase-A Inhibitors” J. Cancer 2014, 135, 751-762. (SCI: 7.316)(52/245, ONCOLOGY) Times Cited: 6
  4. Ke, Y. Y.; Coumar, M. S.; Shiao, H. Y.; Wang, W. C.; Chen, C. W.; Song, J. S.; Chen, C. H.; Lin, W. H.; Wu, S. H.; Hsu, J. T.; Chang, C. M.; Hsieh, H. P.* “Ligand Efficiency Based Approach for Efficient Virtual Screening of Compound Libraries” J. Med. Chem. 2014, 83, 226-235. (corresponding author) (SCI: 7.088)(5/63, CHEMISTRY, MEDICINAL) Times Cited: 11
  5. Wang, W.C.; Shiao, H. Y.; Lee, C. C.; Fung, K. S.; Hsieh, H. P.* “Anaplastic Lymphoma Kinase (ALK) Inhibitors: A Review of Design and Discovery” MedChemComm. 2014, 5, 1266–1279. (corresponding author) (SCI: 5.121)(18/63, CHEMISTRY, MEDICINAL) Times Cited: 20
  6. Chang Hsu, Y.; Ke, Y. Y.; Shiao, H. Y.*; Lee, C. C.; Lin, W. H.; Chen, C. H.; Yen, K. J.; Hsu, J. T.; Chang, C.; Hsieh, H. P.* “Facile Identification of Dual FLT3-Aurora A Inhibitors: A Computer-Guided Drug Design Approach” ChemMedChem, 2014, 5, 953-961. (Selected as the Front Cover) (corresponding author) (SCI: 3.540)(34/63, CHEMISTRY, MEDICINAL) Times Cited: 25

2013

  1. Hou, C.C.; Tsai, T. L.; Su, W. P.; Hsieh, H. P.; Yeh, C. S.; Shieh, D. B.; Su, W. C. “Pronounced Induction of Endoplasmic Reticulum Stress and Tumor Suppression by Surfactant-free Poly(lactic-co-glycolic acid) Nanoparticles via Modulation of the PI3K Signaling Pathway” J. Nanomedicine. 2013, 8, 2689–2707. (SCI: 6.4)(28/276, PHARMACOLOGY & PHARMACY) Times Cited: 10
  2. Shiao, H. Y.; Coumar, M. S.; Chang, C. W.; Ke, Y. Y.; Chi, Y. H.; Chu, C. Y.; Sun, H. Y.; Chen, C. H.; Lin, W. H.; Fung, K. S.; Kuo, P. C.; Huang, C. T.; Chang, K. Y.; Lu, C. T.; Hsu, J. T.; Chen, C. T.; Jiang, W. T.; Chao, Y. S.; Hsieh, H. P.* “Optimization of Ligand and Lipophilic Efficiency To Identify an in Vivo Active Furano-Pyrimidine Aurora Kinase Inhibitor” Med. Chem. 2013, 56, 5247–5260. (NSC-101-2113-M-400-002-MY4) (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 36
  3. Wang, X.; Wu, E.; Wu, J.; Wang, T. L.; Hsieh, H. P.; Liu, X.* “An Antimitotic and Antivascular Agent BPR0L075 Overcomes Multidrug Resistance and Induces Mitotic Catastrophe in Paclitaxel-Resistant Ovarian Cancer Cells” PLoS One. 2013, 8, e65686. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 21
  4. Wu, J. M.; Chen, C. T.; Coumar, M. S.; Lin, W. H.; Chen, Z. J.; Hsu, J. T.; Peng, Y. H.; Shiao, H. Y.; Lin, W. H.; Chu, C. Y.; Wu, J. S.; Lin, C. T.; Chen, C. P.; Hsueh, C. C.; Chang, K. Y.; Kao, L. P.; Huang, C. Y.; Chao, Y. S.; Wu, S. Y.*; Hsieh, H. P.*; Chi, Y. H.* “Aurora kinase inhibitors reveal mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules” Natl. Acad. Sci. U. S. A. 2013, 110, E1779-1787. (NSC-101-2113-M-400-002-MY4) (corresponding author) (SCI: 11.205)(8/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 34
  5. Peng, Y. H.; Shiao, H. Y.; Tu, C. H.; Liu, P. M.; Hsu, J. T.; Amancha, P. K.; Wu, J. S.; Coumar, M. S.; Chen, C. H.; Wang, S. Y.; Lin, W. H.; Sun, H. Y.; Chao, Y. S.; Lyu, P. C.; Hsieh, H. P.*; Wu, S. Y.* “Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors” Med. Chem. 2013, 56, 3889-3903. (NSC-101-2113-M-400-002-MY4) (corresponding author) (SCI: 7.446)(3/62, CHEMISTRY, MEDICINAL) Times Cited: 76
  6. Shionome, Y.; Lin, W. H.; Shiao H. Y.; Hsieh H. P.; Hsu J. T.; Ouchi, T.* “A Novel Aurora-A Inhibitor, BPR1K0609S1, Sensitizes Colorectal Tumor Cells to 5-Fluorofracil (5-FU) treatment” J. Biol. Sci. 2013, 9, 403-411. (SCI: 6.582)(57/295, BIOCHEMISTRY & MOLECULAR BIOLOGY) Times Cited: 10
  7. Hsu, K. C.; Hung, H. C.; Horng, J. T.; Fang, M. Y.; Chang, C. Y.; Li, L. T.; Chen, Y. C.; Chou, D. L.; Chang, C. W.; Hsieh, H. P.; Yang, J. M.; Hsu, J. T.* “Parallel Screening of Wild-type and Drug-resistant Targets for Anti-resistance Neuraminidase Inhibitors” PLoS One. 2013, 8, e56704. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 9
  8. Ke, Y. Y.; Shiao, H. Y.; Hsu, Y. C.; Chu, C. Y.; Wang, W. C.; Lee, Y. C.; Lin, W. H.; Chen, C. H.; Hsu, J. T.; Chang, C. W.; Lin, C. W.; Yeh, T. K.; Chao, Y. S.; Coumar, M. S.*; Hsieh, H. P.* “3D-QSAR-Assisted Drug Design: Identification of a Potent Quinazoline-Based Aurora Kinase Inhibitor” ChemMedChem. 2013, 8, 136-148. (corresponding author) (SCI:3.466)(32/62, CHEMISTRY, MEDICINAL) Times Cited: 25
  9. Hsieh, H. P.; Chen, A. C.; Villarante, N. R.; Chuang, G. J.*; Liao, C. C.* “Substituent Effects on the Photorearrangements of Unsymmetrically Substituted Diazinobarrelenes” RSC Adv., 2013, 3, 1165-1178. (SCI: 3.361)(81/178, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 3

2012

  1. Shiao, H. Y.*; Kuo, C. C.; Horng, J. T.; Shih, S. R.; Chang, S. Y.; Liao, C. C.; Hsu, J. T.; Amancha, P. K.; Chao, Y. S.; Hsieh, H. P.* “An Efficient, Mild and Scalable Synthesis of Bioactive Compounds Containing the Angelicin Scaffold” Chin. Chem. Soc. 2012 59, 1548-1554. (Selected as the Front Cover) (NSC-98-2119-M-400-001-MY3) (corresponding author) (SCI:1.967)(119/178, CHEMISTRY, MULTIDISCIPLINARY) Times Cited: 5
  2. Yeh, J. Y.; Coumar, M. S.; Shiao, H. Y.; Lin, T. J.; Lee, Y. C.; Hung, H. C.; Ko, S.; Kuo, F. M.; Fang, M. Y.; Huang, Y. L.; Hsu, J. T.; Yeh, T. K.; Shih, S. R.; Chao, Y. S.; Horng, J. T.*; Hsieh, H. P.* “Anti-influenza Drug Discovery: Identification of an Orally Bioavailable Quinoline Derivative through Activity- and Property-Guided Lead Optimization” 2012, 9, 1546-1550. (corresponding author) (SCI:3.466) (32/62, CHEMISTRY, MEDICINAL) Times Cited: 5
  3. Liu, L.; Beck, H.; Wang, X.; Hsieh, H. P.; Mason, R. P.; Liu, X.* “Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts” PLoS One 2012, 7, e43314. (SCI: 3.24)(26/72, MULTIDISCIPLINARY SCIENCES) Times Cited: 23
  4. Hsu, J. T.; Yeh, J. Y.; Lin, T. J.; Li, M. L.; Wu, M. S.; Hsieh, C. F.; Chou, Y. C.; Tang, W. F.; Lau, K. S.; Hung, H. C.; Fang, M. Y.; Ko, S.; Hsieh, H. P.*; Horng, J. T.* “Identification of BPR3P0128 as an Inhibitor of Cap-Snatching Activities of Influenza Virus” Agents Chemother. 2012 56, 647-657. (corresponding author) (SCI: 5.191)(57/276, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY) Times Cited: 40
  5. Shiao, H. Y.*; Chiang, N. J.; Hsieh, H. P.* “Anaplastic Lymphoma Kinase (ALK) Inhibitors: New Cancer Breakthroughs for Lung Cancer ” Cancer Res. Pract. 2012, 27, 143-156. (corresponding author) (awardee invited article)
  6. Lin, W. H.; Song, J. S.; Lien, T. W.; Chang, C. Y.; Wu, S. H.; Huang, Y. W.; Chang, T. Y.; Fang, M. Y.; Yen, K. J.; Chen, C. H.; Chu, C. Y.; Hsieh, H. P.; Chen, Y. R.; Chao, Y. S.; Hsu, J. T.* “A High-throughput Cell-based Screening for L858R/T790M Mutant Epidermal Growth Factor Receptor Inhibitors ” Anticancer Res. 2012, 32, 147-151. (SCI: 2.48)(210/242, ONCOLOGY) Times Cited: 3

 Patent Granted

  1. Tsou, L. K.; Niu, G. H.; Hsieh, H. P.; Zhang, M.; Wen Z. H.; Sung, P. J. “Briarane Compounds and Their Use “, US Provision 63/428,303, Nov. 28, 2022.
  2. Hsieh, H. P.; Yen, W. C.; Wu, S. Y.; Li, M. C.; Lin, W. H.; Ke, Y. Y. “Inhibitors of TAM Receptors “, US Provision 63/399,404, Aug. 19, 2022.
  3. Hsieh, H. P.; Lee, K. H.; Lin, W. H.; Shih, C. “以雜環化合物作為激酶抑制劑的治療用途”, TW I757722, Mar. 11, 2022-April 10, 2040.
  4. Hsieh, H. P.; Lee, K. H.; Lin, W. H.; Shih, C. “Heterocyclic Compounds as Kinase Inhibitors for Therapeutic Uses​”, WO/2019/223632, April 9, 2020.
  5. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “Fused Multicyclic Compounds as Protein Kinase Inhibitors”, KR1718386B1, March 21, 2017-Sep. 22, 2029.
  6. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors”, KR1703941B1, 7, 2017- -Nov. 9, 2029.
  7. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, IN279196B, Jan. 20, 2017-April 22, 2029.
  8. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, EP2276346B1, Nov. 23, 2016-April 22, 2029.
  9. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, KR1667822B1, Oct. 19, 2016-April 22, 2029.
  10. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, CA2722220C, June 7,2016-April 22, 2029.
  11. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “做為蛋白質激酶抑制劑之稠合多環化合物”, 0, March 23, 2016-Sep. 22, 2029.
  12. Lin, C. C.; Chang, WHW; Uang, B. J.; Chang, J. Y.; Chen, J. C.; Hsieh, H. P. “組織蛋白酶Ｓ抑制劑”, TWI516479, Jan 11, 2016-Dec. 6, 2030.
  13. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, AU2009241469, Aug. 20,2015-April 22, 2029.
  14. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors”, JP5781934, July 24, 2015-Nov. 9, 2029.
  15. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “Fused Multicyclic Compounds as Protein Kinase Inhibitors”, US9006252, April 14, 2015-Mar. 24, 2032.
  16. Lin, C. C.; Chang, WHW; Uang, B. J.; Chang, J. Y.; Chen, J. C.; Hsieh, H. P. “Cathepsin S inhibitors”, US8895497, Nov. 25, 2014-Dec. 6, 2030.
  17. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “作為極光激酶抑制劑的稠合雙環嘧啶化合物”, 4, Oct. 29,2014-April 22, 2029.
  18. Hsieh, H. P.; Yeh, J. Y.; Hsu, T. A.; Shih, S. R.; Horng, J. T.; Chang S. Y.; Chao, Y. S. “化合物於製造治療病毒感染的藥物之用途”, TWI457121, Oct. 21, 2014-June 11, 2029.
  19. Hsieh, H. P.; Yeh, J. Y.; Hsu, T. A.; Chao, Y. S. “Quinoline Compounds and their Use for Treating Viral Infection”, US8710079, April 29, 2014-April 21, 2031.
  20. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, JP5502072, March 20, 2014-April 22, 2029.
  21. Hsieh, H. P.; Chang, J. Y.; Kuo, C. C.; Chao, Y. S. “治療癌症的醫藥組成物”, TWI415852, Nov. 21, 2013-June 11, 2029.
  22. Hsieh, H. P.; Yeh, J. Y.; Hsu, T. A.; Chao, Y. S. “喹啉化合物及其用以治療病毒性感染之用途”, TWI410245, Oct. 1, 2013-April 22, 2031.
  23. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “Fused Multicyclic Compounds as Protein Kinase Inhibitors”, EP2331530, Aug. 21, 2013-Sep. 22, 2029.
  24. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “Fused Bicyclic and Tricyclic Pyrimidine Compounds as EGFR Kinase Inhibitors”, US8507502, Aug. 13, 2013– 9, 2029.
  25. Hsieh, H. P.; Coumar, M. S.; Chao, Y. S. “做為蛋白質激酶抑制劑之稠合多環化合物”, TWI400242, July 1, 2013-Sep. 23, 2029.
  26. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Lin, W. H; Chen, Y. R.; Chao, Y. S. “作為酪胺酸激酶抑制劑之稠合雙環及多環嘧啶化合物”, TWI385174, Feb. 11, 2013-Nov. 9, 2029.
  27. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “作為極光激酶抑制劑之稠合雙環嘧啶化合物”, TWI363627, May 11, 2012-April 29, 2029.
  28. Jiaang, W. T; Chao, Y. S.; Hsieh, H. P. “吡咯啉啶化合物”, TWI362388, April 21, 2012-Aug. 25, 2026.
  29. Hsieh, H. P.; Coumar, M. S.; Hsu, T. A.; Wu, S. Y.; Chao, Y. S. “Fused Bicyclic Pyrimidine Compounds as Aurora Kinase Inhibitors”, US8138194, March 20, 2012-April 22, 2029.
  30. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds”, CA2437104, March 6, 2012-Aug 13, 2023.
  31. Hsieh, H. P.; Hsu, T. A.; Chao, Y. S.; Chou, Y. C.; Wang, S. T. “引藻萃取物” , TWI356705, Jan. 21, 2012-Oct. 1, 2028.
  32. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.; “Pyrrolidine Compounds”, CA2559611, Jan. 17, 2012-Mar 9, 2025.
  33. Hsieh, H. P.; Chang, J. Y.; Kuo, C. C.; Chao, Y. S. “Coumarin Compounds and Their Use for Treating Cancer”, US8058427, November 15, 2011-June 10, 2029.
  34. Hsieh, H. P.; Hsu, T. A.; Chao, Y. S.; Chou, Y. C.; Wang, S. T. “Extracts from Chlorella” US8048426, Nov. 1, 2011-April 30, 2029.
  35. Hsieh, H. P.; Hsu, T. A.; Hwang, D. R. “抑制Ｃ型肝炎病毒感染之倍半帖內酯類化合物及其醫藥組成物”, TWI344959, July 11, 2011-April 1, 2024.
  36. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W., “抑制冠狀病毒之醫藥組合物”, TWI343808, June 21, 2011-May 28, 2024.
  37. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W., “抑制冠狀病毒之醫藥組合物”, TWI343809, June 21, 2011-May 28, 2024.
  38. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W., “抑制冠狀病毒之醫藥組合物”, TWI343810, June 21, 2011-May 28, 2024.
  39. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds as Inhibitors of Tubulin Polymerisation for the Treatment of Angiogenesis-related Disorders”, EP1506960, April. 6, 2011-Aug. 7, 2023.
  40. Hsieh, H. P; Mahindroo, N.; Hsu, T. A.; Huang, C. F.; Chen, X.; Chao, Y. S. “吲哚化合物”, 8, December 1, 2010 – December 11, 2024.
  41. Hsieh, H. P.; Tung, Y. S.; Liou, J. P.; Chang, J. Y.; Chao, Y. S. “Anti-Tumor Compounds”, 7, December 1, 2010 – December 15, 2025.
  42. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.; “Pyrrolidine Compounds”, CN1942186, Oct. 06, 2010-Mar 9, 2025.
  43. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, CA2598788, Aug. 3, 2010-Aug. 27, 2027.
  44. Hsieh, H. P.; Hsu, T. A.; Chao, Y. S.; Chou, Y. C.; Wang, S. T. “Extracts from Chlorella”, Singapore, 152154, July 15, 2010-Oct. 8, 2028.
  45. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, US7741495, June 22, 2010 – August 31, 2027.
  46. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, 日本特許第4521428號, May 28, 2010 – August 31, 2027.
  47. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P.; “Pyrrolidine Compounds”, US7687504, Mar. 30, 2010-Mar 9, 2025.
  48. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds”, US7632955, December 15, 2009 – December 12, 2022.
  49. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “芳香羰吲哚化合物”, TWI317634, December 1, 2009 – December 11, 2022.
  50. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “吲哚啉磺胺化合物”, TWI315304, October 1, 2009 – August 31, 2027.
  51. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, KR10-0916989, September 4, 2009 – August 31, 2027.
  52. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, AU2007214336, June 4, 2009 – August 31, 2027.
  53. Hsu, T. A.; Hsieh, H. P.; Chao, Y. S.; Chen, C. M.; Jan, J. T.; Liu, H. W. “Treatment of Coronavirus Infection”, US7544712, June 9, 2009 – May 28, 2024.
  54. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, GB2441396, May 13, 2009 – August 31, 2027.
  55. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds,” US7528165, May 5, 2009 – December 12, 2022.
  56. Hsieh, H. P; Mahindroo, N.; Hsu, T. A.; Huang, C. F.; Chen, X.; Chao, Y. S. “吲哚化合物”, TWI304066, December 12, 2008 – December 11, 2024.
  57. Hsieh, H. P.; Tung, Y. S.; Liou, J. P.; Chang, J. Y.; Chao, Y. S. “Anti-Tumor Compounds,” US7456289, November 25, 2008 – December 15, 2025.
  58. Liou, J. P.; Chang, J. Y.; Hsieh, H. P. “Indoline-sulfonamides compounds”, NZ561060, November 13, 2008 – August 31, 2027.
  59. Hsieh, H. P; Mahindroo, N.; Hsu, T. A.; Huang, C. F.; Chen, X.; Chao, Y. S. “Indole Compounds” , US7449478, November 11, 2008 – December 3, 2024.
  60. Jiaang, W. T; Chao, Y. S.; Hsieh, H. P. “Pyrrolidine Compounds”, US7425633, September 16, 2008 – August 28, 2026.
  61. Jiaang, W. T; Chen, X.; Wu, S. Y.; Chao, Y. S.; Hsieh, H. P. “咯啶化合物”, TWI299039, July 21, 2008 – March 9, 2025.
  62. Hsieh, H. P.; Tung, Y. S.; Liou, J. P. Chang, J. Y.; Chao, Y. S. “抗腫瘤化合物”, TWI296195, May 1, 2008 – December 27, 2025.
  63. Jiaang, W. T; Chen, X.; Wu, S. Y.; Hsieh, H. P.; Chao, Y. S. “Pyrrolidine Compounds”, KR7038951, April 12, 2008 – August 28, 2
  64. Hsu, T. A.; Hsieh, H. P.; Juan, L. J; Chang, S. Y.; Kuo, Y. H. “一種抗病毒之醫藥組成物”, TW I293248, February 11, 2008 – May 21, 2023.
  65. Hsieh, H. P.; Liou, J. P.; Chang, J. Y.; Chang, C. W. “Indole Compounds”, US6933316, August 23, 2005 – December 12, 2022.
  66. Burrows, C. J.; Hsieh, H. P. “Steroidal Polyamines”, US5610149, 1997.

Comments are closed.